NCCN 2021 Virtual Congress: Hematologic Malignancies™
Thursday, October 14 – Saturday, October 16, 2021

Disclosure Information

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Congress Co-Chairs

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Ranjana H. Advani, MD
Bristol-Myers Squibb Company: Consulting Fee
Celgene Corporation: Consulting Fee
Cytier Therapeutics: Grant/Research Support
Forty Seven, Inc.: Grant/Research Support
Genentech, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyte Corporation: Consulting Fee
Janssen Pharmaceutica Products, LP: Grant/Research Support
Kura Oncology, Inc.: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
Pharmacyclics: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee
sanofi-aventis U.S.: Consulting Fee
Seattle Genetics, Inc.: Grant/Research Support

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support; Scientific Advisor
BMS/Celgene/Juno: Scientific Advisor
Celgene Corporation: Consulting Fee
Genentech, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Natalie S. Callander, MD
Ronald S. Go, MD
Thomas M. Habermann, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jennifer R. Brown, MD, PhD
AbbVie, Inc.: Consulting Fee
Acerta/AstraZeneca: Consulting Fee
BeiGene: Consulting Fee
Bristol-Myers Squibb/Juno/Celgene: Consulting Fee
Catapult Therapeutics: Consulting Fee
Eli Lilly and Company: Consulting Fee
Genentech/Roche: Consulting Fee
Gilead Sciences, Inc.: Grant/Research Support
Invectys Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Consulting Fee
Loxo/Lilly: Grant/Research Support
MEI Pharma Inc.: Consulting Fee
MorphoSys AG: Consulting Fee
Nextcea, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Rigel Pharmaceuticals, Inc.: Consulting Fee
Secura Bio: Grant/Research Support
Sun Pharma: Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support

Jorge J. Castillo, MD
AbbVie, Inc.: Grant/Research Support; Honoraria
BeiGene: Grant/Research Support; Honoraria
Janssen Pharmaceutica Products, LP: Honoraria
Pharmacyclics: Grant/Research Support; Honoraria
Roche Laboratories, Inc.: Honoraria
TG Therapeutics, Inc.: Grant/Research Support

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Beth Christian, MD
Acerta Pharma: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
Celgene Corporation: Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support
Immunomedics, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Grant/Research Support
MorphoSys AG: Consulting Fee
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support
Teva Pharmaceuticals Industries Ltd: Grant/Research Support
Triphase Accelerator: Grant/Research Support
Verastem Oncology: Consulting Fee

Daniel J. DeAngelo, MD, PhD
AbbVie, Inc.: Grant/Research Support
Amgen Inc.: Consulting Fee
Blueprint Medicines: Grant/Research Support
GlycoMimetics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Consulting Fee
Kite Pharma: Consulting Fee
Pfizer Inc.: Consulting Fee

Aaron T. Gerds, MD, MS
AbbVie, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Constellation Pharmaceuticals: Consulting Fee
CTI BioPharma Corp.: Consulting Fee
Kartos Therapeutics, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
PharmaEssentia Corporation: Consulting Fee
Promedior, Inc.: Consulting Fee
Sierra Oncology: Consulting Fee

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Agios, Inc.: Scientific Advisor
Bayer HealthCare: Grant/Research Support
Blueprint Medicines: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Incyte Corporation: Grant/Research Support; Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Carol Ann Huff, MD
AstraZeneca Pharmaceuticals LP: Honoraria
GlaxoSmithKline: Honoraria
Oncopeptides: Honoraria
sanofi-aventis U.S.: Honoraria

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
GlaxoSmithKline: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Michaela Liedtke, MD
Allogene Therapeutics: Grant/Research Support
Alnylam Pharmaceuticals, Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor
Caelum Biosciences, Inc.: Grant/Research Support
Celgene Corporation: Grant/Research Support
GlaxoSmithKline: Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor
Kite Pharma: Scientific Advisor
Kura Oncology, Inc.: Scientific Advisor
Natera, Inc.: Scientific Advisor
Oncopeptides: Scientific Advisor
sanofi-aventis U.S.: Scientific Advisor
Seattle Genetics, Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

Matthew J. Matasar, MD
Bayer HealthCare: Consulting Fee; Grant/Research Support; Honoraria
Daiichi-Sankyo Co.: Consulting Fee
Genentech, Inc.: Consulting Fee; Grant/Research Support; Honoraria
GlaxoSmithKline: Grant/Research Support; Honoraria
IGM Biosciences: Grant/Research Support
Immunovaccine Technologies: Grant/Research Support; Honoraria
Janssen Pharmaceutica Products, LP: Grant/Research Support; Honoraria
Juno Therapeutics, Inc.: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Equity Interest/Stock Options
Pharmacyclics: Grant/Research Support; Honoraria
Rocket Medical: Consulting Fee; Grant/Research Support
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support; Honoraria
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support; Honoraria
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Honoraria
Teva Pharmaceutical Industries Ltd: Consulting Fee

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Neha Mehta-Shah, MD**
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Bristol-Myers Squibb Company: Consulting Fee
C4 Therapeutics: Consulting Fee
Celgene Corporation: Grant/Research Support
Corvus Pharmaceuticals: Grant/Research Support
Daiichi-Sankyo Co.: Consulting Fee; Grant/Research Support
Genentech, Inc.: Grant/Research Support
Innate Pharma, Inc.: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
Kyowa Hakko Kirin Co., Ltd.: Consulting Fee
Ono Pharmaceutical Co., Ltd.: Consulting Fee
Secura Bio: Consulting Fee; Grant/Research Support
Verastem Oncology: Grant/Research Support

**Alice S. Mims, MD, MS**
AbbVie, Inc.: Consulting Fee
Astellas Pharma US, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Genentech, Inc.: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee
Kura Oncology, Inc.: Consulting Fee
Syndax Pharmaceuticals Inc.: Consulting Fee

**Vivian G. Oehler, MD**
Blueprint Medicines: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee
Pfizer Inc.: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

**Alexander E. Perl, MD**
Abbvie, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Actinium Pharmaceuticals: Honoraria; Scientific Advisor
Astellas Pharma US, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Celgene Corporation: Honoraria; Scientific Advisor
Daiichi-Sankyo Co.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Forma Therapeutics: Consulting Fee
Fujifilm Corporation: Grant/Research Support
Genentech, Inc.: Honoraria; Scientific Advisor
Loxo Oncology, Inc.: Honoraria; Scientific Advisor
Sumitomo Dainippon: Consulting Fee; Scientific Advisor
Syndax Pharmaceuticals Inc.: Honoraria; Scientific Advisor

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Grant/Research Support; Scientific Advisor; Aprea Therapeutics: Scientific Advisor; Astellas Pharma US, Inc.: Scientific Advisor; Bristol-Myers Squibb Company: Scientific Advisor; Celgene Corporation: Scientific Advisor; Foghorn Therapeutics: Scientific Advisor; Genentech, Inc.: Scientific Advisor; Gilead Sciences, Inc.: Scientific Advisor; GlycoMimetics, Inc.: Scientific Advisor; Karyopharm Therapeutics: Scientific Advisor; Kiadis Pharma: Scientific Advisor; Novartis Pharmaceuticals Corporation: Scientific Advisor; Syndax Pharmaceuticals Inc.: Scientific Advisor; Syros Pharmaceuticals: Scientific Advisor; Takeda Pharmaceuticals North America, Inc.: Scientific Advisor; Teva Pharmaceutical Industries Ltd: Grant/Research Support

Mazyar Shadman, MD, MPH
AbbVie, Inc.: Consulting Fee; Grant/Research Support; Adaptimmune Therapeutics plc.: Consulting Fee; Adaptive Biotechnologies: Consulting Fee; AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support; Atara Biotherapeutics, Inc.: Consulting Fee; Grant/Research Support; BeiGene: Consulting Fee; Grant/Research Support; Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support; Celgene Corporation: Grant/Research Support; Eli Lilly and Company: Consulting Fee; Epizyme, Inc.: Consulting Fee; Genentech, Inc.: Consulting Fee; Grant/Research Support; Genmab A/S: Grant/Research Support; Innate Pharma, Inc.: Consulting Fee; Kite Pharma: Consulting Fee; MorphoSys AG: Consulting Fee; Mustang Bio: Consulting Fee; Grant/Research Support; Pharmacyclics: Consulting Fee; Grant/Research Support; Sound Biologics: Consulting Fee; Sunesis Pharmaceuticals, Inc.: Grant/Research Support; TG Therapeutics, Inc.: Consulting Fee; Grant/Research Support

Neil P. Shah, MD, PhD
Bristol-Myers Squibb Company: Grant/Research Support; Taiho Pharmaceuticals Co., Ltd.: Honoraria

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Presenting Faculty (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

B. Douglas Smith, MD
Bristol-Myers Squibb Company: Consulting Fee
Celgene Corporation: Consulting Fee
Celularity Inc.: Consulting Fee
Jubilant Pharma: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee

Jakub Svoboda, MD
Adaptive Biotechnologies: Consulting Fee; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Atara Biotherapeutics, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Genmab A/S: Consulting Fee
Imbruvia Therapeutics L.P.: Consulting Fee
Incyte Corporation: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Pharmacyclics: Consulting Fee; Grant/Research Support
Seattle Genetics, Inc.: Consulting Fee; Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support

Jennifer A. Woyach, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee
Eli Lilly and Company: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
Karyopharm Therapeutics: Grant/Research Support
MorphoSys AG: Grant/Research Support
Newave Pharmaceuticals Inc.: Scientific Advisor
Pharmacyclics: Consulting Fee; Grant/Research Support
Schrodinger, Inc.: Grant/Research Support

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Disclosure Information

Faculty Disclosures

Moderators

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Gaurav Goyal, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jeremy S. Abramson, MD, MMSc
Allogene Therapeutics: Consulting Fee
AstraZeneca Pharmaceuticals LP: Honoraria
BeiGene: Consulting Fee; Honoraria
bluebird bio, Inc.: Consulting Fee
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support; Honoraria
Celgene Corporation: Consulting Fee; Grant/Research Support; Honoraria
C4 Therapeutics, Inc.: Consulting Fee
Epizyme, Inc.: Consulting Fee
Genentech, Inc.: Consulting Fee
Genmab A/S: Honoraria
Incyte Corporation: Honoraria
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Kymera Therapeutics: Consulting Fee
MorphoSys AG: Consulting Fee
Mustang Bio: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Ono Pharmaceutical Co., Ltd.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Honoraria
Seattle Genetics, Inc.: Grant/Research Support

Muhamed Baljevic, MD
Amgen Inc.: Grant/Research Support
Aptitude Health: Honoraria
Atheneum: Consulting Fee
BMS/Celgene Corporation: Consulting Fee; Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Cardinal Health Specialty Solutions: Scientific Advisor
Cardinal Health Specialty Solutions Oncology: Honoraria
Adaptive Biotechnologies: Honoraria
Coleman Research Group, Inc.: Consulting Fee
Exelixis Inc.: Grant/Research Support
Gerson Lehrman Group, Inc.: Consulting Fee
Guidepoint Global, LLC.: Consulting Fee
Janssen Research & Development, LLC.: Scientific Advisor
Karyopharm Therapeutics: Honoraria; Scientific Advisor
Oncopeptides: Scientific Advisor
Putnam Associates: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
Faculty Disclosures

Moderators (continued)

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Andrew T. Kuykendall, MD
AbbVie, Inc.: Honoraria
Blueprint Medicines: Grant/Research Support; Honoraria; Product/Speakers Bureau
Celgene Corporation: Consulting Fee; Grant/Research Support; Honoraria; Product/Speakers Bureau
CTI BioPharma Corp.: Honoraria
Incyte Corporation: Product/Speakers Bureau; Scientific Advisor
Novartis Pharmaceuticals Corporation: Honoraria; Product/Speakers Bureau
PharmaEssentia Corporation: Honoraria; Scientific Advisor
Prelude Therapeutics: Grant/Research Support; Scientific Advisor
Protagonist Therapeutics, Inc.: Consulting Fee; Honoraria; Product/Speakers Bureau

Gabriel Mannis, MD
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Agios, Inc.: Consulting Fee; Scientific Advisor
Astellas Pharma US, Inc.: Scientific Advisor
Astex Pharmaceuticals: Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor
Forty Seven, Inc.: Scientific Advisor
Genentech, Inc.: Consulting Fee; Scientific Advisor
Gilead Sciences, Inc.: Grant/Research Support
GlycoMimetics, Inc.: Grant/Research Support
Jazz Pharmaceuticals Inc.: Grant/Research Support
MacroGenics: Consulting Fee
Pfizer Inc.: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.
NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This list includes disclosures of relevant financial relationships submitted to NCCN as of October 8, 2021.